Ipsen presents a range of data on Dysport in different therapy areas

Ipsen’s (Euronext: IPN) US-based biotech arm, Ipsen Biopharmaceuticals, says it will present data on Dysport (abobotulinumtoxinA) related to multiple therapeutic uses.

Dysport is an injectable form of the botulinum toxin type A (BoNT-A), which has been approved in the USA for multiple indications, including last year as a treatment for spasticity in adults.

Highlights of the data, which are being presented at the ongoing American Academy of Neurology meeting in Los Angeles, include a pooled analysis of safety data from four trials involving children, which show that the safety profile of Dysport across age groups is consistent.

In addition, a Phase III, double-blind study confirms that the maximum clinical benefit, as measured by physicians, was obtained after repeat dosing of Dysport in the lower extremity using the most effective dosing regimen in adult post-stroke or traumatic brain injury patients.

Finally, results of a meta-analysis that evaluated the impact of one injection cycle of Dysport on the clinical characteristics of cervical dystonia (CD) and persistence of therapeutic benefits confirmed that the clinical symptoms of CD may not fully return to baseline by 12 weeks following a single injection cycle of Dysport.